What is the 13F Pro Quality Score for TEVA?

13F Pro ranks TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TEVA's current score at https://13fpro.ai/research/TEVA (free sign-up required for the full ranking).

Which hedge funds own the most TEVA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TEVA include BlackRock,, Phoenix Financial Ltd., MENORA MIVTACHIM HOLDINGS LTD.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/TEVA as soon as new 13F filings post.

Where does 13F Pro source TEVA data?

All TEVA PHARMACEUTICAL INDUSTRIES LTD fundamentals and ownership data come directly from SEC EDGAR. TEVA PHARMACEUTICAL INDUSTRIES LTD files with the SEC under CIK 818686. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TEVA in?

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TEVA research updated on 13F Pro?

TEVA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

TEVA PHARMACEUTICAL INDUSTRIES LTD(TEVA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 818686 TEVA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

TEVA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA), a Healthcare sector company. TEVA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), TEVA PHARMACEUTICAL INDUSTRIES LTD reports quarterly revenue of $4.0B, net income of $369.0M, an operating margin of 16.4%. Top institutional holders of TEVA by reported 13-F value include BlackRock,, Phoenix Financial Ltd., MENORA MIVTACHIM HOLDINGS LTD., based on the most recent SEC filings. TEVA trades on the NYSE exchange and files with the SEC under CIK 818686. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TEVA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TEVA PHARMACEUTICAL INDUSTRIES LTD directly from SEC EDGAR.

Revenue

Q1 2026

$4.0B

Net Income

Q1 2026

$369.0M

Free Cash Flow

Q1 2026

$-208.0M

Operating Margin

Q1 2026

16.4%

ROIC

Q1 2026

7.9%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+15.6% YoY

$17.26BFY 2025

FY19 $16.89BFY21 $15.88BFY22 $14.93BFY25 $17.26B

Net Income

+157.6% YoY

$1.41BFY 2025

FY19 $-999.0MFY21 $417.0MFY22 $-2.45BFY25 $1.41B

Operating Income

+198.2% YoY

$2.16BFY 2025

FY19 $-443.0MFY21 $1.72BFY22 $-2.20BFY25 $2.16B

EPS (Diluted)

+155.0% YoY

$1.21FY 2025

FY19 $-0.91FY21 $0.38FY22 $-2.20FY25 $1.21

Total Assets

-7.4% YoY

$40.75BFY 2025

FY19 $57.47BFY21 $47.67BFY22 $44.01BFY25 $40.75B

Total Debt

-13.8% YoY

$3.62BFY 2025

FY19 $4.18BFY21 $2.83BFY22 $4.20BFY25 $3.62B

Op. Cash Flow

+3.7% YoY

$1.65BFY 2025

FY19 $748.0MFY21 $798.0MFY22 $1.59BFY25 $1.65B

Metric	FY 2025	FY 2022	FY 2021	FY 2019	FY 2017	FY 2015
Revenue	$17.26B +15.6%	$14.93B -6.0%	$15.88B -6.0%	$16.89B -24.6%	$22.39B +13.9%	$19.65B
Net Income	$1.41B +157.6%	$-2.45B -686.6%	$417.0M +141.7%	$-999.0M +93.9%	$-16.27B -1124.2%	$1.59B
Operating Income	$2.16B +198.2%	$-2.20B -228.0%	$1.72B +487.4%	$-443.0M +97.5%	$-17.48B -621.6%	$3.35B
EPS (Diluted)	$1.21 +155.0%	$-2.20 -678.9%	$0.38 +141.8%	$-0.91 +94.4%	$-16.26 -993.4%	$1.82
Total Assets	$40.75B -7.4%	$44.01B -7.7%	$47.67B -17.1%	$57.47B -18.6%	$70.61B +30.2%	$54.23B
Total Debt	$3.62B -13.8%	$4.20B +48.3%	$2.83B -32.3%	$4.18B -88.2%	$35.36B +221.2%	$11.01B
Operating Cash Flow	$1.65B +3.7%	$1.59B +99.2%	$798.0M +6.7%	$748.0M -66.4%	$2.23B -59.9%	$5.54B

AI Insight: TEVA Financial Trends

Teva swung from four consecutive quarters of operating losses to sustained profitability, while debt surged back to $5.2B in Q1 2026 after touching near-zero in Q3 2025.

• Operating income turned decisively positive from Q1 2025 onward, reaching $882M in Q3 2025 versus losses of up to -$51M through Q3 2024.

• Net income improved from -$846M in Q2 2024 to +$480M in Q4 2025, marking a full earnings recovery across five quarters.

• Equity grew from $5,373M in Q4 2024 to $8,228M in Q1 2026, reflecting retained earnings and balance-sheet strengthening.

• Revenue grew modestly from $4,164M in Q2 2024 to $4,711M in Q4 2025, with Q1 2026 at $3,982M — typical seasonal softness.

⚠ Total debt spiked to $5,212M in Q1 2026 from just $25M in Q3 2025 — a sharp reversal that warrants explanation on use of proceeds.

⚠ Operating cash flow turned negative at -$40M in Q1 2026 and -$105M in Q1 2025, suggesting seasonal working-capital pressure each first quarter.

⚠ Operating margin compression from $882M in Q3 2025 to $300M in Q4 2025 and $652M in Q1 2026 signals quarter-to-quarter volatility worth monitoring.

AI Insight: TEVA Ratio Trends

Teva has staged a dramatic profitability recovery, swinging from deeply negative margins in mid-2024 to sustained operating profitability through 2025 and into Q1 2026.

• Operating margin recovered from -1.2% in Q3 2024 to 16.4% in Q1 2026, marking a decisive and sustained turnaround.

• ROE swung from -53.2% in Q2 2024 to 17.9% in Q1 2026, reflecting sharply improved earnings quality.

• D/E ratio fell from 0.85 in Q3 2024 to 0.13 by Q1 2025, though it has since rebounded to 0.63 in Q1 2026.

⚠ D/E rose from 0.00 in Q3 2025 back to 0.63 in Q1 2026 — leverage re-acceleration warrants monitoring.

⚠ ROIC collapsed from 48.5% in Q3 2025 to 10.4% in Q4 2025, then partially recovered to 19.4% — volatility signals one-off distortions.

⚠ Operating margin dropped to 6.4% in Q4 2025 before rebounding — seasonal or structural weakness needs clarification.

Get alerted when TEVA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TEVA PHARMACEUTICAL INDUSTRIES LTD including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TEVA

BlackRock, Inc.
$2.0B65,136,464 sh
Phoenix Financial Ltd.
$1.3B42,777,414 sh
MENORA MIVTACHIM HOLDINGS LTD.
$1.2B39,626,383 sh
WCM INVESTMENT MANAGEMENT, LLC
$1.2B40,820,600 sh
Migdal Insurance & Financial Holdings Ltd.
$1.1B37,902,212 sh
FMR LLC
$998.0M33,132,795 sh
Lingotto Investment Management LLP
$836.5M27,770,857 sh
STATE STREET CORP
$535.8M17,790,020 sh
Rubric Capital Management LP
$459.3M15,250,000 sh
Altshuler Shaham Ltd
$334.6M11,463,621 sh

Fund	Value	Shares
BlackRock, Inc.	$2.0B	65,136,464
Phoenix Financial Ltd.	$1.3B	42,777,414
MENORA MIVTACHIM HOLDINGS LTD.	$1.2B	39,626,383
WCM INVESTMENT MANAGEMENT, LLC	$1.2B	40,820,600
Migdal Insurance & Financial Holdings Ltd.	$1.1B	37,902,212
FMR LLC	$998.0M	33,132,795
Lingotto Investment Management LLP	$836.5M	27,770,857
STATE STREET CORP	$535.8M	17,790,020
Rubric Capital Management LP	$459.3M	15,250,000
Altshuler Shaham Ltd	$334.6M	11,463,621

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TEVA on your watchlist

Track score changes the day TEVA PHARMACEUTICAL INDUSTRIES LTD files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TEVA a good stock to buy?

13F Pro's AI-powered analysis of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TEVA are available on the TEVA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TEVA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TEVA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TEVA PHARMACEUTICAL INDUSTRIES LTD's investment landscape.